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MORBIDITY, MORTALITY, AND GRAFT FUNCTION 
IN RENAL TRANSPLANT RECIPIENTS: 
A COMPARISON OF THE EFFECTS OF 
CYCLOSPORINE VERSUS AZATHIOPRINE 
Michael Scott Sherman 
1986 
Some investigators have claimed that cyclosporine is a 
superior immunosuppressive agent compared to azathioprine. In 
order to evaluate this hypothesis in patients treated at Yale-New 
Haven Hospital, charts as well as inpatient and outpatient 
transplantation data sheets were reviewed for all patients who 
received kidney transplants between February 1983 and February 
1985. There were 26 patients in the cyclosporine treatment 
group, 46 patients in the azathioprine treatment group, and 9 
patients started on azathioprine but switched to cyclosporine 
within the first three months for intractable rejection. 
Morbidity, mortality, graft loss, number and severity of 
rejection episodes, and renal function, were compared in the 
renal transplant recipients treated with cyclosporine versus 
those given azathioprine. Analysis was also performed on the 
incidence of rejection in patients switched from cyclosporine to 

azathioprine at three to ten months post transplantation as is 
the policy at Yale. 
Analysis of the background characteristics revealed that 
the cyclosporine group differed from the azathioprine group in 
two areas: age and percent receiving cadaveric grafts. Patients 
treated with cyclosporine were significantly older than those 
immunosuppressed with azathioprine (44.0jf2.5 versus 31.6_+1.9, 
p <. 0 01) . Also, the cyclosporine group had a higher percentage of 
cadaveric grafts implanted (100 percent versus 57.1 percent, 
p<.0001). Both of these differences arose because of the original 
policy in effect for cyclosporine use. Graft source, however, 
was controlled for in that comparisons between the two groups 
were performed for all patients and then repeated using only the 
subgroup of azathioprine treated patients who had received 
cadaveric grafts. 
No difference between the groups was found for patient 
survival, graft survival, or overall patient morbidity (as 
measured by noting number of days hospitalized). These variables 
were compared at both six months and at one year. In addition, 
both groups were found to have experienced the same number of 
rejection episodes, again at both six months and at one year 
following transplantation. Although the total number of 
rejection episodes at one year was the same in both groups, the 
cyclosporine group experienced only half as many serious 
rejections (defined by the need for antithymocyte globulin or 
monoclonal antibodies or by graft loss) over this time period as 
had the azathioprine group ( 0.4-K). 1 versus 0.3 + 0.1 , p<.05). 
. 
Furthermore, although the azathioprine group had more serious 
rejections, their mortality and graft survival was no worse than 
the cyclosporine group. This observation is believed to result 
from improved methods of dealing with serious rejection episodes 
that have not responded to intravenous steroids. 
Based on comparison of serum creatinine values, both at 
three and at six months, renal function was found to be better in 
the azathioprine treated patients at three months (1.50+.10 
versus 2.12+_. 15 mg/dl, p<.001) although this disparity was no 
longer statistically significant at six months (1.67+.18 versus 
2.16+_.20 mg/dl, p>.05). Moreover, the difference at three months 
was no longer evident once serum creatinine values were compared 
only for the cadaveric transplantation patients in each group 
(1.71+.19 versus 2.12+..15, p>.05). Thus, it is likely that the 
overall azathioprine group had better renal function at three 
months than the cyclosporine group because it contained a greater 
number of living related transplant recipients rather than 
because of nephrotoxicity in the cyclosporine group. It is 
however unclear why this did not hold at six months. 
Following a switch from cyclosporine to azathioprine, four 
of sixteen cyclosporine patients experienced rejection within 
three months. However, one episode occured in a patient who had 
been switched eight weeks earlier and another in a person who had 
a viral illness at the time of switch and then rejected one week 
later. Thus, there are only two incidents of rejection (at two 
and four weeks) which appear to be clearly related to the 
withdrawal of cyclosporine. Although there is no control group 

for these patients, even two rejections occuring within one month 
of being switched from cyclosporine to azathioprine seems to be a 
suspiciously high number in patients who were out more than six 
months from their transplant. 
In summary, the current study demonstrated that cyclosporine 
was not found to confer any advantage with regard to either 
patient or graft survival. Nor did cyclosporine treated patients 
require less days of hospitalization post transplantation. 
However cyclosporine treated patients who did suffer rejection 
episodes had less severe ones. The lack of difference in graft 
survival between the two groups may be explained by the 
availability of more effective means of treating rejections in 
azathioprine patients, by the initial use of cyclosporine only in 




Review of Literature 
I. Historical Perspective 
From the first crude attempts at immunosuppression a quarter 
of a century ago to the first clinical trial of cyclosporine in 
1978, immunosuppression of renal allografts has come a long way 
and has been the subject of a great deal of research. In 1959, 
Schwartz and Damashed first demonstrated that 6-mercaptopurine 
(6-MP) had the ability to induce immunological tolerance in adult 
rabbits (1). In the following year, 6-MP was used in renal 
transplant experiments in dogs by Caine (2) and Zukoski and 
coworkers (3). Their efforts showed that albeit tolerance did 
not develop, graft survival was prolonged in some animals. 
In 1961, azathioprine, an imidazolyl derivative of 6-MP, was 
first synthesized (4) . Animal studies soon showed that 
azathioprine possessed less toxicity than 6-MP (5), and it was 
first used in a human renal transplant recipient in 1961 in 
Boston. In the first two patients, there was no evidence of 
increased survival with azathioprine; however, in the following 
year, the first extended success with transplanted kidneys was 
seen (6-7). 
Many centers began to add steroids to their 
immunosuppressive regimens in 1962. Yet for several years, they 
were used only for rejection episodes (8). After reports by 
Starzl et al. (9) and Goodwin et al. (10), the use of both 
azathioprine and steroids together became a standard regimen; and 
even today, the combination - often referred to as conventional 
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immunosuppressive therapy - remains the standard to which all 
other regimens are compared. 
Cyclosporine, formerly known as cyclosporin A, is a fungal 
polypeptide composed of eleven amino acids, one of which is 
unique; most are hydrophobic, making the drug soluble only in 
lipids or organic solvents. First isolated from soil samples by 
the microbiology department at Sandoz, it was shown by Jean Borel 
to have potent immunosuppressive activity in a variety of in 
vitro and in vivo situations (11-12). Some twenty years after 
azathioprine first came into clinical use, Caine introduced 
cyclosporine into clinical practice (13), and in 1978 the first 
clinical trial began in Cambridge (14). 
II. Azathioprine 
The imidazole derivative, azathioprine, interferes with 
blastogenesis (involving DNA and RNA synthesis), which is known 
to be involved in the immune response. This blastogenic response 
can be measured by a variety of radioactive labeling techniques 
and is an early event in T cell response. It is therefore 
believed that azathioprine exerts its major effect by preventing 
the expansion of T lymphocyte clones responding to foreign 
antigens. Moreover, azathioprine effects the inflammatory 
reaction as well as both cell-mediated and humoral immunity (15). 
In vitro, azathioprine is known to alter most T cell markers and 
functions. For example, studies show that it inhibits mixed 
lymphocyte reactions along with the subsequent generation of 
' 
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cytotoxic T cells (16). Azathioprine has also been shown in 
laboratory studies to be particularly active against suppressor T 
cells (17), an effect also found in vivo in renal transplant 
recipients (18). As mentioned earlier, azathioprine is also 
active against B cells but less intensely than against T cells. 
For example, in one investigation, mouse T cell rosettes were 
inhibited by lower doses of the drug than those required for B 
cell rosette inhibition (19). 
Investigators long ago confirmed that azathioprine prolongs 
the survival of transplanted kidneys and other organs (20-21). 
Today, one year mortality for renal transplant recipients treated 
with azathioprine is very low, especially at the major centers. 
For example, a recent review of the statistics for a large 
population of azathioprine treated patients revealed one year 
graft survival of 75 percent and patient survival of 95 percent 
for patients receiving grafts from living related donors; for 
persons receiving cadaveric kidneys, the results were 56 percent 
and 86 percent, respectively (22). 
Although azathioprine is a valuable immunosuppressive agent, 
it does have a number of serious side effects, the most common of 
which is a dose-dependent bone marrow suppression which effects 
mainly the production of white blood cells; in contrast, platelet 
production is rarely affected. Effect on erythrocytes is 
unpredictable; when it does occur, the result is usually a 
normochromic, normocytic anemia. Alopecia is another common, 
albeit less serious, side effect. However it is often transient, 
improving with modification of the azathioprine dose (23). 
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Azathioprine has also been reported to cause hepatic dysfunction 
although rarely of a serious nature. However, while hepatic 
toxicity has clearly been established in experimental animals, it 
is not certain that it occurs in humans in the doses used in 
renal transplant recipients (24). One side effect of 
azathioprine that has been documented is its tendency to 
encourage the development of malignant tumors, either 
pre-existing or grafted with the organ. Penn, who has 
established the International Transplant Tumor Registry, has 
published reports indicating that the incidence of tumors is 
approximately one hundred times greater than in the general 
population for the same age range (25). Yet, it is believed that 
for the stable patient on long term maintenance therapy, 
reduction of the daily dose from about 2.0-2.5 mg/kg to 1.5-2.0 
mg/kg is safe and is associated with a decrease in the occurance 
of malignancy (26). 
Ill. Steroids 
The pharacology of steroids is very complex. They affect 
the immune system in a number of ways, especially at high doses. 
In addition to an effect on T lymphocytes, there is also a 
powerful anti-inflammatory reaction. One recent study showed 
that in therapy of acute rejection with methylprednisolone, the 
clinical effect is readily apparent within one to two hours, 
which is too rapid to be completely explained by a true 
immunosuppressive effect (27). More specifically, 
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corticosteroids have been shown to directly inhibit T cell 
proliferation. High concentrations of corticosteroids lyse mouse 
T cells but not human T cells; nevertheless, T cell proliferation 
is inhibited in human tissue culture (28). Recent investigations 
suggest that steroids reverse in vivo rejection episodes by 
preventing the production of interleukin-2, thus robbing the T 
cells of an essential factor needed for proliferation (29). 
Steroids, however, do not act directly on the interleukin-2 
producing T cell; rather, they inhibit production by preventing 
macrophages from releasing interleukin-1, thereby blocking 
interleukin-1 dependent release of interleukin-2 from activated T 
cells (30). 
The utility of steroids in the treatment of rejection 
episodes was first demonstrated in the early 1960's (31-32). 
Since that time, they have seen frequent use in the prevention of 
chronic rejection and in the treatment of acute rejection crises. 
One group of investigators found that rejection crises recur in 
30 percent of cases after steroids have been discontinued and 
also that almost one-third of all crises are initiated by 
lowering of the steroid dose (33). Clinically, a high 
azathioprine/low steroid regimen is believed to be the best 
option as it provides adequate immunosuppression while minimizing 
steroid related complications (26). Today, the predominant use 
of steroids is in maintenance protocols which also employ 
azathioprine or cyclosporine, or in higher doses to treat acute 
rejection (34). 
With regard to toxicity, steroids can produce many 
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complications and are a major contributor to post-transplantation 
morbidity and mortality. The side effects of steroids include 
growth retardation, a reduced rate of wound healing, 
predisposition to osteoporosis, avascular necrosis, cataracts, 
diabetes, obesity, Cushingoid features, and a number of other, 
less common problems (26). 
IV. Cyclosporine 
The new immunosuppressive agent cyclosporine has shown great 
promise in a variety of organs in addition to the kidney. For 
example, it has been widely used to modify rejection in bone 
marrow transplantation (35). Cyclosporine has a high degree of 
specificity for T cells. Studies show that it inhibits T cell 
proliferation induced by T cell mitogens, but in contrast, the 
action against B lymphocytes is much less (36-38). Several 
groups of investigators have used monoclonal antibodies to 
monitor the T lymphocyte subpopulations of renal allograft 
recipients; such studies have suggested that cyclosporine causes 
a reduction in the ratio of helper-inducer T cells to 
cytotoxic-suppressor T cells (39-40). With regard to mechanism, 
a number of research efforts have shown that cyclosporine 
interferes with the production of lymphokines, especially 
interleukin-2, by the helper T cell. Furthermore, interleukin-1 
production by the macrophage as well as interleukin-3 production 
(colony stimulating factor) are probably inhibited as well 
(41-43), although these are not believed to be as important as 
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the effect on interleukin-2. It is likely that combined 
cyclosporine and steroid therapy is so effective because both act 
on interleulcin-2 although through different mechanisms. Whereas 
cyclosporine acts predominantly on helper T cells, 
corticosteroids prevent interleu kin-1 release from accessory 
cells (34). It has also been shown that cyclosporine does not 
appear to influence the inflammatory granulation response in 
vivo; this is consistent with the clinical observation that 
patients treated with the drug exhibit normal wound healing (44). 
With regard to pharmacodynamics, dosage must be determined on an 
empirical basis because of the erratic absorption that is seen. 
There is, however, a rough correlation between plasma level and 
degree of suppression of rejection of renal allografts (45-46). 
A great number of animal experiments have been performed 
with cyclosporine, documenting the extensive prolongation of 
graft survival made possible by the agent. That cyclosporine is 
a potent inhibitor of allograft rejection has been demonstrated 
for heart, kidney, and skin grafts in a variety of species (36, 
47-51). These will not be reviewed in detail here. However, one 
interesting study showed that a marked synergism existed between 
cyclosporine and antilymphocyte serum; although this study was 
performed in rats, the authors suggest that their findings may be 
relevant in clinical practice (52). Since 197S, many clinical 
studies have been done. One recent investigation produced data 
showing that cyclosporine provides for excellent graft survival 
in those recipients who differed from living donors by one 
haplotype and in recipients who were considered highly reactive 
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by mixed lymphocyte reaction (53). A number of clinical trials 
have been performed comparing cyclosporine to conventional 
therapy; these are reviewed in the discussion. 
Like other drugs used for immunosuppression, cyclosporine 
has a long list of side effects. This includes nephrotoxicity, 
hepatotoxicity, lymphomas, dermatologic disorders hirsutism, 
rashes, skin thickening, gastrointestinal disturbance (anorexia, 
nausea, failure to gain weight), neurological problems (tremor, 
malaise and depression, burning sensation in limbs), 
cardiovascular effects (hypertension, fluid retention), and 
dental changes (gingival hypertrophy) (23). 
In renal transplant recipients, the nephrotoxicity can be 
worrisome. This effect has been shown to be dose-related and 
reversible if the cyclosporine is stopped. It was noted in the 
Oxford trial that when patients were converted to azathioprine 
and prednisolone at three months, they underwent a rapid and 
significant improvement in their renal function (46, 54). Bone 
marrow recipients have also exhibited a return to normal renal 
function upon discontinuation of cyclosporine (55). The 
nephrotoxicity of this drug was first suggested by Caine and 
colleagues after the completion of an early clinical trial (14). 
This led to the recommendation that it only be used in patients 
whose kidneys were already making urine following transplantation 
(56). Interestingly enough, prior to the first report of renal 
toxicity in humans, no mention of this had ever been reported, 
even in ischemic kidneys exposed to cyclosporine (57). However, 
more recent experimental studies in the rat have demonstrated 
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proximal tubular damage, especially in the thick descending limb 
of the loop of Henle (58); yet it should be appreciated that this 
research involved very large doses of cyclosporine - 50-100 
mg/kg. The presence of worsened renal function seen after liver 
and bone marrow transplantation further illustrates that 
nephrotoxicity is a real side effect (59-64). 
One of the greatest difficulties of using cyclosporine in 
renal transplantation is differentiating as to whether 
deteriorating renal function is secondary to acute rejection or 
stems from cyclosporine toxicity. This is made even more 
difficult since cyclosporine can suppress the obvious signs of 
rejetion (fever, graft swelling, tenderness). While a renal 
biopsy may prove helpful, the cellular infiltrates that are 
commonly seen in the grafts of cyclosporine treated patients can 
be difficult to interpret. A suggestion made by one team of 
investigators is that given a creatinine of greater than 300 
raicromol/L, rejection should be assumed and therapy with 
methylprednisolone begun. If the problem really is rejection, 
then a marked fall in creatinine should be seen after the use of 
the intravenous steroids. If on the other hand, either the serum 
creatinine is less than 300 micro in ol/L or the patient fails to 
respond to the methylprednisolone, a diagnosis of nephrotoxicity 
is made (regardless of cyclosporine levels), and the dose is 
halved (65). 
Another major side effect is the inreased incidence of 
lymphoma. In one early study, a very high rate of occurence was 
seen, with three of twenty-nine patients getting lymphomas (37). 
‘ 
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Subsequent studies have suggested a lower rate of lymphoma 
occurence though. In summary then, cyclosporine is a major new 
immunosuppressive agent which has received a great deal of 
attention in recent years. The many encouraging studies which 
have been performed suggest that cyclosporine may help produce 
dramatic increases in graft and patient survival, especially for 
transplanted organs other than kidneys, since the success rate 
for renal transplants is so high especially at some of the major 
centers that a statistically significant increase might be 
difficult to detect. 
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Introduction and Purpose 
The recent approval of the new immunosuppressive agent, 
cyclosporine, for routine clinical usage has been predicted to 
have a major impact on the area of transplantation surgery. By 
allowing better control of graft rejection, its use has been 
shown to be associated with results far better than those seen 
with more conventional treatment for a number of transplantable 
organs. Thus, many centers which previously had been reluctant 
to perform heart or liver transplantation have now begun to 
undertake these procedures with renewed enthusiasm. With renal 
allografts as well, some investigators believe that graft 
recipients have experienced less frequent rejection with 
cyclosporine. At Yale-New Haven Hospital, for example, 
cyclosporine was first reserved for patients designated as being 
at increased risk of graft rejection. However in spite of the 
extremely high cost of the drug, just one year after its 
introduction, it had become the standard treatment for all 
patients receiving cadaveric kidneys. 
Although many studies have recently appeared comparing the 
efficacy of cyclosporine to that of more traditional 
immunosuppressive regimens, there are still many questions 
remaining to be answered. By studying renal allograft recipients 




1. Comparison of morbidity and mortality in patients treated 
with cyclosporine versus those treated with azathioprine. 
2. Comparison of number and severity of rejection episodes 
in the two groups. 
3. Comparison of long term renal function in the two groups. 
4. Evaluation of incidence of rejection in cyclosporine 
treated patients following replacement of cyclosporine 
by azathioprine after three to ten months as per Yale 
protocol. 
5. Evaluation of graft survival, graft function, morbidity, 
and mortality in patients originally treated with 
azathioprine but later switched to cyclosporine because 
of intractable rejection. 
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Materials and Methods 
To explore the effect of cyclosporine on morbidity, 
mortality, rejection, and graft function in renal transplant 
recipients, data was collected on patients receiving transplants 
at Yale-New Haven Hospital from February 1983 through February 
1985. During the period studied, all transplants were performed 
by two transplantation surgeons, Dr. M. Wayne FI ye (former 
Director of Organ Transplantation) and Dr. Martin Schiff 
(Department of Surgery - Section of Urology), thus eliminating 
one potential source of variability. Sources of information 
included patient charts, summary sheets containing relevant lab 
values and drug dosages during inpatient treatment, clinic 
records, and the personal files of Dr. Margaret Bia. 
The patient population was broken down into three groups: a 
study group (N=26) consisting of patients receiving prednisone 
plus cyclosporine between December 1983 (when it first became 
available) and February 1985; a control group ( N = 4 9 ) consisting 
of patients who were transplanted between February 1983 and 
February 1985 and treated with prednisone plus azathioprine; and 
an "azathioprine failure" group (N=9) consisting of graft 
recipients who were originally begun on azathioprine but later 
switched to cyclosporine because of inadequate immunosuppression. 
Thus a total of 84 patients were studied. Most cadaveric 
patients were placed on cyclosporine once it became available. 
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In order to include as many high risk and cadaveric recipients in 
the azathioprine group as in the cyclosporine group, the period 
of analysis of azathioprine treated patients extended back to ten 
months before cyclosporine was introduced. The following 
convention is used throughout this study: Group C - cyclosporine 
(study) group, Group A - azathioprine (control) group, Group F 
azathioprine failure group. 
Although the azathioprine failure group is somewhat 
artificial in that it is the result of clinical decision rather 
than treatment protocol, these "crossover" patients are included 
for the sake of completeness since they were transplanted during 
the period of study. It is acknowledged that they do not 
represent current clinical practices (given that all cadaveric 
graft recipients are now receiving cyclosporine from the onset). 
Thus, whereas data from Groups C and A are directly compared 
using appropriate statistical tests, that of Group F is merely 
tabulated and presented. 
Initially, between October 1983 and October 1984, only high 
risk patients were treated with cyclosporine. These patients 
were high risk in that they not only received cadaveric kidneys 
but also fulfilled one of the following criteria: age greater 
than 50, history of diabetes, prior failed transplant, or 
possessing greater than 50 percent HLA-directed antibodies prior 
to transplantation. Beginning in November 1984, the policy was 
altered to require that all cadaveric graft recipients be given 
cyclosporine. As previously explained, the reason that the 
azathioprine or control group includes those patients receiving 
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grafts during the ten month period prior to the introduction of 
cyclosporine is to help dilute the effect of having made the 
azathioprine treated cohort a "low risk" group by virtue of 
having selected out for cyclosporine treatment those patients 
most likely to encounter complications. Thus, an attempt was 
made to include a similar number of high risk patients in Group A 
as in group C. 
One patient, who received a graft from her identical twin, 
is excluded from analysis as she received no immunosuppression. 
All patients received prednisone as part of their 
immunosuppressive regimen. The protocol for administration of 
immunosuppressive medications was as follows. Azathioprine was 
always given in the amount of 2 mg/kg beginning on the day of 
transplantation. Cyclosporine was given in quantities sufficient 
to maintain serum levels of 50-150 ng/ml by HPLC following an 
initial loading dose of either 15 mg/kg P.0. or 5 mg/kg I.V.. 
In all patients, prednisone was started at a dose of 2-4 mg/kg on 
the day of transplantation and tapered to .25-.40 mg/kg by the 
end of the first month. 
Before undertaking an analysis of the data, it was first 
necessary to characterize the three cohorts. Thus, as part of a 
preliminary comparison, the following information was gathered on 
each patient: age, history of diabetes, source of kidney 
(cadaveric versus living related), number having lost a prior 
transplant, and degree of prior sensitization (measured as the 
« 
percentage of HLA antigens against which antibodies were 
detected). Both peak and most recent values were recorded in the 
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assessment of prior sensitization. Note is made of diabetes as 
it is the main preexisting renal disease which has been found to 
be associated with increased patient morbidity after 
transplantation. With regard to results, the following 
information was collected. Data was gathered on occurence of 
graft loss (as indicated by either nephrectomy or return to 
dialysis), number of days hospitalized, and number of rejection 
episodes. All were examined at both six months and one year 
after transplantation. Number of days hospitalized was tabulated 
in order to obtain a general indication of morbidity, as renal 
transplant patients are frequently hospitalized for reasons other 
than rejection (e.g. infections secondary to immunosuppression). 
Patient mortality at one year was also recorded and compared 
between groups. A review of the variables collected for each 
group and the comparisons made are listed in Table 1 (for groups 
A and C) and Table 2 (for group F). Furthermore, additional 
variables examined in group C alone are listed in Table 3. These 
tables also contain units of measure for the different variables. 
It should be recognized that number of rejection episodes is 
necessarily greater than graft loss as many rejection episodes 
were satisfactorily treated and reversed. Rejection was 
recognized in the chart review by noting an intensification in 
immunosuppressive therapy (125-500 mg of methylprednisolone for 
3-5 consecutive days, anti-thymocyte globulin, or monoclonal 
antibodies) along with a concoramitant elevation in serum 
creatinine concentration. Most were confirmed by renal biopsy. 
Moreover, rejection events were further classified as to whether 
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they were severe. A severe episode was defined as one in which 
loss of graft occured or anti-thymocyte globulin or monoclonal 
antibodies were required. A mild rejection was one treated only 
with pulse steroids. 
Graft function was also compared between groups, by noting 
serum creatinine concentration at both three and six months 
post-transplant. Because this value was recorded to provide an 
indication of stable graft function at the times noted, patients 
in the midst of rejection episodes (at three or six months) had a 
creatinine value recorded that represented stable renal function 
following treatment for the rejection incident. Cyclosporine was 
frequently held initially in patients with primary graft 
non-function. Thus for individuals in the cyclosporine and 
azathioprine failure groups, record was made of the number of 
days elapsing between transplantation surgery and introduction of 
cyclosporine. 
We also attempted to examine whether rejection occurred when 
cyclosporine treated patients were switched to azathioprine. 
Most cyclosporine treated patients had their immunosuppressive 
regimens modified sometime between the third and tenth month 
following transplantation since the Yale protocol calls for all 
cyclosporine treated renal transplant patients to be switched to 
azathioprine sometime during this time interval. Exceptions 
include patients experiencing chronic rejection, one patient who 
was found to be allergic to azathioprine, and one pediatric graft 
recipient, all of whom were continued on cyclosporine 
indefinitely. For those cyclosporine treated graft recipients 
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who were switched, the month at which this switch occured was 
noted as well as the appearance and timing of any rejection 
episodes during the next three months. 
With regard to data manipulation and analysis, all 
information was entered into an IBM 4381 mainframe computer and 
statistical tests carried out using the Statistical Analysis 
Systems (SAS) software package. The SAS variable names used to 
represent the different types of data collected are listed in 
Tables 1-3 (for use in reviewing the computer generated 
appendix). A summary of all collected data may be found in the 




Analysis of Background Characteristics 
In order to first obtain a picture of the different groups 
with respect to variables that might affect the results, factors 
such as age, source of graft, presence of diabetes, graft number, 
peak percent antibodies, and recent percent antibodies were 
compared. Table 4 contains a comparison of these background 
variables. 
There were only two items which differed significantly 
between the cyclosporine and azathioprine treated patients: 
source of graft and age. 100 percent of the cyclosporine treated 
patients received cadaveric kidneys as compared to 57.1 percent 
of azathioprine treated patients (p=.0001). This is as expected 
as only recipients of cadaveric grafts were treated with 
cyclosporine during the period studied. Moreover, Group C 
patients were older than Group A patients: 4 4.0+^2.5 versus 
3l.6+_1.9 years (p<.001). A visual comparison of ages may be seen 
in figure 1. No significant differences were seen for graft 
number, meaning how many patients in each group were receiving 
their first, second, or third kidney transplant. Preformed 
antibodies to HLA antigens are thought by some to predict graft 
outcomes if the level is high. However, the peak percent 
antibodies as well as the most recent percent antibodies were 
similar in each group. There were also a similar number of 
diabetics in Groups A and C. 
Table 5 lists background data for the azathioprine failures. 
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Not surprisingly, this group closely resembles Group A, whose 
patients were started and maintained on azathioprine. 67 percent 
of the Group F patients received cadaveric grafts, and the mean 
age was 32.6_+5.5 years. 
Analysis of Morbidity, Mortality, and Graft Loss 
Table 6 compares morbidity, mortality, and graft loss for 
Group C versus Group A, and Table 7 presents the same results for 
Group F. None of these indicators of outcome differed 
significantly between Groups C and A. 
80.8 percent of the cyclosporine treated patients were alive 
at one year as compared with 91.8 percent of those treated with 
azathioprine. All of the azathioprine failures survived to one 
year. By six months, 19.2 percent of the cyclosporine treated 
patients had lost their grafts, while the figure was 24.5 percent 
for the azathioprine patients. Values for graft loss at one year 
are 26.9 percent and 26.5 percent respectively. These 
differences are not significant. 11.1 percent (1 of 9) of Group 
F experienced graft loss by six months; and in these patients, 
there was no further loss between six months and one year. 
Overall morbidity was assessed by counting number of days 
hospitalized. During the first six months following 
transplantation, Group C patients spent an average of 49.0+6.5 
days hospitalized, while Group A patients spent an average of 
39.2_+3.8 days as inpatients. Corresponding figures for the first 
year are 64.0+13.0 days for Group C versus 44.0j-4.7 days for 
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Group A. Whereas cyclosporine treated patients tended to spend 
more time in the hospital, the differences were not significant 
at the .05 level. Group F tended to have the longest hospital 
stay of all, averaging 65.7+4.7 days and 7 5.3+5.7 days for six 
months and one year respectively. This is likely explained by 
the prolonged stay required to treat their multiple rejections. 
Figure 2 is a bar graph comparing the number of days hospitalized 
during the first six months for the three groups, and Figure 3 
contains the same information for the first year. 
Analysis of Rejection Episodes and Graft Function 
Number and severity of rejection episodes were evaluated as 
was serum creatinine concentration. These findings are 
summarized in Table 8, which compares the data for Group A versus 
Group C and in Table 9, which summarizes the same information for 
Group F. 
Cyclosporine treated patients experienced an average of 
0.9;+. 1 rejections during the first six months and 1.l+_. 2 during 
the first year. Values for azathioprine treated patients are 
1.0-+.1 and l.lj-.l, respectively. These numbers are very close to 
one another, and indeed there are no statistically significant 
differences between the two groups, either at six months or at 
one year. These data are also presented in Tables 10 and 11, 
which tabulate the percentage of patients in each group with one, 
two, three, or four rejections at six months and at one year, 
respectively. These charts illustrate that at six months, 19.2 
■ 
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percent of cyclosporine treated patients had experienced more 
than one rejection episode versus 16.3 percent for the 
azathioprine treated patients. At one year, the respective 
values are a virtually identical 26.9 percent and 26.5 percent. 
However, examination of the number of serious rejection 
episodes at one year reveals that cyclosporine treated patients 
experienced markedly fewer serious rejection episodes than did 
azathioprine treated patients. Group C patients had an average 
of 0.4+^.1 serious rejection episodes each whereas for Group A 
patients, the value is 0.8+_.l (p<.05 by Student’s t-test). 
Stated another way, no member of Group C had greater than 1 
serious rejection episode, whereas 10.1 percent of Group A 
patients had such occurences (Table 12). Group F patients 
experienced an average of 1.3+_. 2 serious rejections each, which 
is consistent with their eventually being switched to 
cyclosporine because of inadequate immunosuppression. 
Graft function was assessed by recording serum creatinine 
concentration at both 3 and at 6 months. As seen on Table 8, at 
3 months, the Group A patients had significantly better renal 
function than the Group C patients, with creatinine values of 
1.50j-.10 and 2.12-f.l5 mg/dl respectively (p<.001). By 6 months 
however, although azathioprine treated patients still tended to 
have lower serum creatinine concentrations than those subjects 
treated with cyclosporine (1.67+.18 versus 2.16j^.20 mg/dl), the 
difference was not statistically significant. This was not 
explained by switch to azathioprine in patients originally 
treated with cyclosporine since only three patients had been 
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switched by the six month mark. Group F patients were remarkably 
stable with regard to creatinine concentration, averaging 
1.66+.21 mg/dl at 3 months and 1.67+^.25 mg/dl at 6 months. 
Figures 4 and 5 are histograms illustrating serum creatinine 
concentration at 3 and at 6 months respectively for Group A; 
Figures 6 and 7 depict the same for Group C; and finally, 
histograms for Group F are shown in Figures 8 and 9. 
Analysis of Results for Cadaveric Graft Recipients Only 
Whereas all Group C patients received cadaveric grafts, only 
57.1 percent of the Group A patients did. In order to control 
for this selection bias, the data was re-examined looking only at 
patients who had received cadaveric kidneys and the results 
tabulated. 
Background comparisons for this subset of patients are 
listed in Table 13. As with the comparison for the entire group, 
the cyclosporine patients are significantly older: 44„0+_2.5 
versus 34.1+_2.2 years (p<.01). However, now only 3.6 percent of 
the azathioprine treated patients are diabetic versus 23.1 
percent of the cyclosporine treated patients (p<.05). There 
remains no difference with regard to graft number, peak percent 
antibodies, or recent percent antibodies. 
Table 14 compares morbidity, mortality, and graft loss for 
cadaveric recipients in Group C versus Group A. There are still 
no significant differences for one year survival or number of 
days hospitalized, either at six months or at one year. 
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Comparing just cadaveric recipients, Group A cadaveric recipients 
tended to have higher graft loss than cyclosporine treated 
patients (39.5 percent for cyclosporine versus 19.9 percent for 
azathioprine) at six months and 39 percent versus 27 percent 
respectively at one year. These differences did not reach 
statistical significance. 
Finally, number and severity of rejection episodes and serum 
creatinine concentration are compared for cadaveric graft 
recipients (Table 15). As before, there is no difference between 
the two groups with regard to total number of rejection episodes 
at both six months and at one year. However, cadaveric 
recipients in Group A still had a higher number of more serious 
rejections during the first year than did Group C patients 
(1.0+_. 1 versus 0.4-j^.l; p=.0001). Although serum creatinine 
concentration tended to be higher in cyclosporine treated 
patients at either 3 months (2.12+..15 mg/dl for Group C versus 
1,71+..19 mg/dl for Group A) or at six months (2.16-+.20 mg/dl for 
Group C versus 1.73+.. 19 mg/dl for Group A); the differences are 
not statistically significant. 
Analysis of Outcome for Cyclosporine Patients Switched to Azathioprine 
Of 26 patients who were treated with cyclosporine, 16 were 
switched to azathioprine sometime between the third and tenth 
month. Of the remaining 10 patients, most lost their kidney or 
expired prior to being switched, while a few were kept on 
cyclosporine because of subacute or chronic rejection. Of those 
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16 who were switched, 4 (25%) suffered one rejection episode each 
over the next 3 months. Timing of the rejection episode for 
these four patients (relative to the switch) was as follows: 1 
week (R.K.), 2 weeks (I.P.), 4 weeks (F.S.), and 8 weeks (R.B.). 
It should be noted however that the patient who had a rejection 
episode 1 week after being switched had an antecedant viral 
infection, and it cannot be determined whether the rejection was 
the result of the viral infection or whether it stemmed from the 
withdrawal of cyclosporine. Furthermore, it is not clear that 
the rejection that occurred in R. B. at eight weeks can be 
attributed to cyclosporine switch since the interval from switch 
to rejection was so long. Thus in only two patients (I.P., F.S.) 






Direct comparison of cyclosporine and azathioprine treated 
patients was performed for all variables studied. Recognizing 
that azathioprine failures do exist, a separate group of such 
patients was evaluated but not compared directly to the other two 
because of its heterogeneity and the fact that it is the product 
of clinical decision rather than protocol. This study includes 
patients placed in the cyclosporine group because of the presence 
of one or more of the following high risk criteria: age greater 
than 50, history of diabetes, prior failed graft, or HLA 
antibodies greater than 50%; or, after November 1984, it included 
any recipient of a cadaveric graft. As mentioned in the 
materials and methods section, azathioprine treated patients from 
the ten month period prior to the introduction of cyclosporine 
were included in the study in an attempt to minimize the effect 
of having made the azathioprine cohort a low risk population. 
For the most part, this strategy was successful. Comparison 
of the background characteristics reveals that the azathioprine 
and cyclosporine treated patients differed significantly in only 
two variables: source of graft and age. The former was 
unavoidable since no recipient of a living related donor kidney 
was given cyclosporine (p<.0001). The latter was significant at 
the pC.OOl level with cyclosporine patients being older (44.0+2.5 
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versus 31.6+.1.9 years). Both factors should be kept in mind in 
interpretation of the results. Graft number, recent and peak 
percent antibody, and the frequency of diabetes did not differ 
significantly. 
Whereas it might have been helpful to control for the 
disparity in age by selecting a subset of younger cyclosporine 
treated patients for comparison with the azathioprine treated 
group, this was not possible as only 13 cyclosporine treated 
patients were less than 50 years of age. 
Morbidity, Mortality, and Graft Loss 
Patient mortality did not differ between azathioprine and 
cyclosporine treated individuals. Patient survival at one year 
was 80.8% for the cyclosporine treated patients and 91.8% for 
those on azathioprine. This difference did not prove to be 
statistically significant at the p<.05 level. These figures are 
low compared to published data (66), an observation believed to 
be attributable to the large number of high risk patients who 
received grafts at Yale. Even when only cadaveric graft 
recipients in the azathioprine group were compared to the 
cyclosporine cohort, there was still not a significant difference 
in patient survival (Table 14). 
It is interesting to note that all azathioprine failures 
survived to one year. Since these patients were switched to 
cyclosporine because they had multiple rejections on 
azathioprine, they probably would have had less favorable results 
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than the azathioprine group had they remained in the that group 
and not been switched to cyclosporine. 
Graft survival at six months was calculated and found to be 
81.8 percent for cyclosporine versus 75.5 percent for 
azathioprine; at one year, graft survival was 74.1 percent and 
74.5 percent respectively. Neither comparison was statistically 
significant. Moreover, a subgroup consisting of azathioprine 
treated cadaveric patients was compared to cadaveric patients 
given cyclosporine in order to control for graft source. Again 
the differences in graft survival were not significant at either 
six months or at one year. One year graft survival was 89 
percent for recipients in Group F. This graft survival is quite 
good and appears to justify switching these patients from 
azathioprine to cyclosporine for unrelenting rejection episodes 
(Table 7). 
As a general measure of morbidity, number of days 
hospitalized was determined at both six months and at one year. 
By six months after undergoing transplantation, patients in the 
cyclosporine group had spent an average of 49.0+6.5 days 
hospitalized, versus 39.2_+3.8 days for those given azathioprine. 
At one year, the figures are 64.0+13.0 and 44.0+4.7 days for 
cyclosporine and azathioprine patients respectively. Although 
cyclosporine patients tended to spend a greater number of days 
hospitalized, the difference is not significant for either time 
interval (Table 6). Again, controlling for graft source by 
comparing only cadaveric graft recipients, differences in number 
of hospitalized days were still not significant (Table 14). 
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Number and Severity of Rejection Episodes 
Number of rejection episodes was asessed at both six months 
and at one year. In addition, number of serious rejection 
episodes for the first year was compared, serious being defined 
as requiring therapy with either antilymphocyte serum or 
monoclonal antibodies, or resulting in graft loss. At six months 
19.2 percent of the cyclosporine group and 16.3 percent of the 
azathioprine cohort had experienced two or more rejections (Table 
10). This difference is not significant at the .05 level (Table 
I 
8). At one year, corresponding values were 26.9 percent and 26.5 
percent for the cyclosporine and azathioprine groups 
respectively, also not significant (Table 11). Once again, 
analysis of the data was performed limiting the patients studied 
to recipients of cadaveric grafts in both groups. Yet again, 
differences failed to reach significance (Table 15). 
Assessment of number of severe rejections during the first 
year revealed that cyclosporine treated patients had fewer 
serious rejection episodes than did those graft recipients on 
azathioprine (Table 12). In fact, cyclosporine patients averaged 
only half as many serious rejections (0.4-f.l versus 0.8+_.l, 
p<.05) . Stated differently, no cyclosporine patient had more 
than one severe episode whereas 10.1% of those subjects treated 
with azathioprine had two or more such episodes. Similar results 
were demonstrated when the number of serious rejections were 
compared in just the cadaveric recipients of Group A versus Group 
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C (Table 15). Patients in the azathioprine failure cohort 
averaged 1.3+_. 2 serious rejection episodes during the first year. 
This is consistent with the fact that these patients were 
switched because of serious rejection. The high number of 
serious episodes in this group is noteworthy because, had these 
patients remained in the azathioprine group, they would have made 
that group appear even worse, hence accentuating a difference 
which is already statistically significant. 
The Yale data concerning frequency and severity of 
rejections is consistent with the findings of the Minnesota group 
(67). Based on a study of cyclosporine versus standard 
immunosuppression, they showed that while cyclosporine does not 
decrease the incidence of rejection, the clinical features are 
often mild and one does not see the florid manifestations of 
acute rejection which occur in patients being treated with 
azathioprine. 
Given that the azathioprine group had a larger number of 
severe rejections and the fact that serious occurences require a 
prolonged course of antilymphocyte serum or monoclonal 
antibodies, one would expect that they would have accumulated a 
greater number of hospital days. However, comparison of number 
of days hospitalized revealed that there was no statistical 
difference between the two groups. It is lenown that other than 
rejection, the other major cause of morbidity in immunosuppressed 
.transplant recipients is infectious disease. Considering that 
the cyclosporine patients are significantly older and hence at 




reasonable to hypothesize that cyclosporine patients spent as 
much time in the hospital as the azathioprine patients because of 
infections. Moreover, this is consistent with the evidence that 
cyclosporine is a more potent immunosuppressive agent than 
azathioprine. This hypothesis would require further analysis 
of the number of infections in each group for confirmation. 
Given that the azathioprine group experienced more severe 
rejection, one might expect that these patient would have higher 
rates of graft loss as well as other measures of morbidity. Yet, 
as discussed earlier, such is not the case. Probably, the most 
plausible explanation stems from the great advances (especially 
with the availability of 0KT3 monoclonal antibodies) made in the 
treatment of rejections. Thus, although the azathioprine 
patients had more severe rejections, the newer therapeutics used 
to treat rejection are so effective in reversing it that their 
outcome is no different from that of patients who have more mild 
rejection. Without the benefit of antilymphocyte serum or 
monoclonal antibodies, it is probable that cyclosporine treated 
patients would have had better results in terms of patient and 
graft survival. It is also possible that no difference in graft 
survival between groups was seen because of the small numbers in 
each group. In summary, while azathioprine and cyclosporine 
appear to have the same net effect on kidney survival, the 
severity of rejection is less in cyclosporine treated patients. 
With regard to complications, there is some evidence that 
patients treated with cyclosporine are also more prone to 
lymphomas. This was first recognized shortly after cyclosporine 
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was first used in renal allograft recipients (69). With regard 
to the Yale population, only one of the 26 cyclosporine patients 
developed a lymphoma, which proved to be fatal; so it does not 
appear to have been a major cause of morbidity or mortality. 
There is also experimental evidence which supports the 
supposition that cyclosporine is associated with a higher 
incidence of lymphomas. One group showed that in the presence of 
cyclosporine, EBV infected B lymphocytes will proliferate 
unchecked because the T cell dependent control of this 
proliferation is inhibited (70). 
Comparison with Other Clinical Trials 
The Yale data do not support the concept that cyclosporine 
improves cadaveric graft survival. Other studies have reached 
conflicting conclusions. At this point, it is useful to briefly 
review the findings of some of the major clinical trials which 
have been performed. In one of the first clinical trials, Starzl 
and colleagues obtained very good results with cyclosporine, with 
one year graft survival of almost 80 percent (71). This study 
was uncontrolled and involved 66 consecutive recipients of 67 
cadaveric renal allografts. Starzl attributed his results to the 
use of steroids as well as cyclosporine; however it should be 
appreciated that the steroid component was only a small fraction 
of that previously used with azathioprine. 
Another early controlled trial, this one by Caine et al., 
also praised the efficacy of cyclosporine. They found that use 
' 
34 
of cyclosporine was associated with an increase in one year 
actuarial graft survival from 50 — 55 percent to over 80 percent 
in recipients of cadaveric renal allografts (72). Furthermore 12 
of 34 patients (35 percent) never required concurrent steroid 
therapy. On the other hand, in one of the first controlled 
clinical trials of cyclosporine versus azathioprine plus 
prednisone, Morris found that there was essentially no difference 
in graft survival at three months (38). There are two problems 
with this study: the small number of patients and the very 
limited follow-up. 
Often quoted is a the long term retrospective analysis by 
Caine and colleagues, which compared cyclosporine to conventional 
therapy consisting of azathioprine plus prednisone. In this 
study, the cyclosporine patients did not receive steroids. They 
found that at four years after transplantation, there was no 
difference in terms of patient survival (86 percent for 
cyclosporine versus 76 percent for conventional therapy), graft 
survival (70 percent for cyclosporine versus 62 percent for 
conventional therapy), or incidence of rejection. While the 
cyclosporine patients did do slightly better, the differences 
were small and not statistically significant (73). 
Another major study was the Canadian Multicenter Trial, in 
which cyclosporine plus prednisone were compared to the best 
available standard therapy. In this case however, while there 
was no significant difference in patient survival (96.6 percent 
for cyclosporine versus 86.4 percent for azathioprine), 
cyclosporine patients did do substantially better in terms of 
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graft survival (80.4 percent and 64.0 percent respectively). 
There was no difference in number of rejections (74). They 
conclude that cyclosporine is the drug of choice for maximizing 
graft survival in recipients of cadaveric renal allografts. 
Another large study, the European Multicenter trial, 
published results similar to those of the Canadian study. They 
gave cyclosporine without steroids ("to avoid 
over-immunosuppression") and compared it with azathioprine plus 
steroids; only cadaveric graft recipients were studied. They 
found no difference in patient survival (94 percent for 
cyclosporine versus 92 percent for controls). For one year graft 
survival though, cyclosporine treated patients had significantly 
better results (72 percent versus 52 percent for controls). 24 
of 84 patients were switched from cyclosporine to conventional 
therapy by the end of the first year. No comparison of incidence 
of rejection was included in this report (75). 
A final clinical trial that will be summarized is that of 
the University of Minnesota group. They undertook a prospective 
randomized clinical trial in which cyclosporine plus prednisone 
was compared to standard therapy, the latter including 
anti1ymphocyte globulin as well as azathioprine plus prednisone. 
This study found that there was no difference in terms of graft 
survival at 22 months (83.5 percent with cyclosporine versus 82.3 
percent for conventional therapy). If only cadaveric graft 
recipients were analyzed, there was still no difference in graft 
survival (84 percent with cyclosporine versus 80 percent for 
There was also no difference in patient standard therapy). 
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survival, with that figure being greater than 92 percent for all 
categories. They also did separate analyses focusing on source 
of graft and presence of diabetes and found that cyclosporine did 
not confer an advantage. They did however find that cyclosporine 
patients had a lower incidence of rejection episodes (67). 
Najarian and his colleagues attributed the lack of better results 
with cyclosporine to improved management with conventional 
therapy . 
In summary then, while none of the four large trials 
summarized found that use of cyclosporine improved patient 
survival, two of the four concluded that it improved graft 
survival. In a brief summary of the major clinical trials, Evans 
gives several reasons for the mixed results. He points out that 
conventional therapy often varied from center to center as well 
as among centers within the same study. He also attributes the 
discrepancies to differences in cyclosporine protocols (both 
dosage schedules and variability of adjuvant steroids (31). One 
interesting point is that all of the centers publishing data 
generally have excellent transplantation surgeons and 
nephrologists. 
Renal Function 
As an indicator of graft function, serum creatinine 
concentrations were recorded at both three and at six months. 
Only stable values were used; patients in the midst of an acute 
rejection had their next stable creatinine value recorded 
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instead. It should be recognized that of 19 cyclosporine 
patients for whom six month creatinine values were available, 
only three had already been switched to azathioprine (all at 
about two months earlier). Thus, for the most part, the six 
month creatinine concentrations for the cyclosporine group may be 
said to accurately reflect function of kidneys exposed to 
cyclosporine. 
At three months, cyclosporine treated patients had 
significantly worse renal function than did those subjects given 
azathioprine (2.12+..15 mg/dl versus 1.504-.10 mg/dl, pC.001). By 
six months however, there was no longer any significant 
difference. If only cadaveric graft recipients are compared, 
then there is no difference at either point. This suggests that 
the cyclosporine group had higher creatinine values at three 
months because it possessed significantly more cadaveric grafts. 
However it is not clear then why there is no difference in 
function at six months. Since in the groups as a whole and in 
just the cadaveric recipients of each group, serum creatinine 
concentrations always tended to be higher in cyclosporine treated 
patients, it is possible that these differences would have 
reached statistical significance had larger numbers of patients 
been evaluated. 
Other groups which have studied renal function in patients 
treated with cyclosporine have found similar results. Najarian 
et al. have published results which show a mean three month 
creatinine concentration of 1.98 mg/dl (s.d.-+.61) and a mean six 
month creatinine concentration of 2.00 mg/dl (s.d.+.,52) in 
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patients treated with cyclosporine (67). These values are very 
close to those of the Yale patients. Of note is the fact that 
this study excludes ten patients who were switched to alternate 
day cyclosporine after three months for nephrotoxicity. In the 
Canadian Multicenter Trial which studied cadaveric graft 
recipients only, cyclosporine patients were found to have 
significantly higher creatinine values at six weeks (2.6 rag/dl 
versus 2.0 mg/dl, p=.03) (74). A two year follow-up study which 
compared cyclosporine with azathioprine was published by the 
Cambridge group (23). Their data, which suggests that 
cyclosporine does not have a long terra negative effect on renal 
function, is consistent with the Yale data. It should be 
appreciated that assessing the effect of cyclosporine on renal 
function can be difficult, even utilizing biopsies. For example, 
although it is known to be nephrotoxic, many of the morphological 
features of nephrotoxicity overlap with those of rejection. 
Separation of the two effects is not straightforward (23). 
Post Cyclosporine Switch Data 
Of the 26 patients in the cyclosporine group, 16 were 
switched over to azathioprine between three and ten months after 
undergoing transplantation as per protocol. Of the ten who were 
not switched, one was a pediatric patient (which are kept on 
cyclosporine indefinitely); a few were kept on cyclosporine 
because of chronic rejection; and the remainder eitner died or 
lost their grafts while still on cyclosporine. Of the 16 who 
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were changed over to azathioprine, four suffered rejection during 
the following three months: one each at one, two, four, and eight 
weeks after being switched. All of these patients were switched 
at either six or seven months after the original operation. 
Because one patient rejected eight weeks after being switched, it 
is not clear that his rejection may be directly attributed to the 
withdrawal of cyclosporine. In addition, the patient who 
suffered a rejection episode one week after being changed over to 
azathioprine had a viral infection, and it is unclear whether 
this rejection was set off by the viral infection or by the 
change in immunosuppressive regimen. Thus, only two (12.5 
percent) of sixteen patients had rejections that were directly 
linked to the replacement of cyclosporine by azathioprine. 
Given the lack of any type of control group as well as the 
small numbers involved, it is difficult to comment on the 
significance of this finding. However, for patients who received 
renal transplants at least six months earlier, even two 
rejections out of sixteen patients during a four week period 
seems to be rather high. Therefore, the only conclusion that can 
be drawn is that cyclosporine treated patients may have been at 
increased risk of rejection following the switch to azathioprine, 
but the relationship is far from clear. 
In one animal study, dogs which had received cadaveric renal 
allografts were able to be converted from cyclosporine to 
azathioprine at three months without increased graft loss (76). 
However, the endpoint quoted in this study is graft loss not 
rejection, and results obtained in animals do not always extend 
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to humans. The Minnesota group has published results of a 
randomized clinical trial comparing cyclosporine versus 
azathioprine (67). They report on four patients who were 
switched from cyclosporine to azathioprine; of that number, one 
had an acute rejection episode within two weeks, while the others 
gradually improved. However, these four patients were switched 
because of cyclosporine-related nephrotoxicity rather than by 
protocol. Thus, this data cannot be directly compared to the 
Yale results. Finally, in one recent study, 14 renal transplant 
patients were switched from cyclosporine to azathioprine at three 
months. Of this number, eleven patients had no rejection 
episodes following the switch, while three patients suffered 
severe rejection leading to graft loss, all during the second 
week after switch (54). They conclude that there is an increased 
incidence of serious rejection after patients are switched. 
However, because two of the patients were already in midst of 
severe rejection crises at the time of switch, it is difficult to 
draw any firm conclusions from this report. Unfortunately, 
little has been published in this area, and much of what has been 
published is difficult to interpret, given the small numbers of 
patients and differences in reasons for switch; clearly, further 
research is needed in this area. 
Summary 
In summary, this study shows that at Yale-New Haven Hospital 
between February 1983 and February 1985, patient survival in 

cyclosporine and azathioprine treated patients was similar. In 
addition, graft survival was similar for the two groups at six 
and at twelve months. Number of hospital days in each group was 
also similar. The number of rejections was similar but less 
severe with cyclosporine. Finally, renal function tended to be 
worse with cyclosporine but only reached statistical significance 
at three months. 
Conclusion 
Cyclosporine is a potent immunosuppressive agent. Although 
graft survival and number of rejection episodes are similar to 
conventional therapy, severity of rejections is improved. 
Further study is needed with more patients to determine whether 




Table 1. Background Characteristics and Results 




Variable Unit of Measure SAS Name 
Source of Kidney C=cadaveric SOURCE 
Age at Operation 
L=living related 
years AGE 




Peak Percent Antibodies percent ABPEAK 
Most Recent Percent Antibodies percent ABREC 
Results 
Mortality at 1 Year A=alive MORTAL 
Graft Loss at 6 Months 
D=dead 
Y=graft lost L0SS6M0 
Graft Loss at 1 Year 
N=graft functioning 
Y=graft lost LOSS 1YR 
Period Hospitalized 
-During First Six Months 
N=graft functioning 
days DAYS6M0 
-During First Year days DAYS 1YR 
Rejection Episodes 
-During First Six Months REJ6M0 
-During First Year REJ1YR 
Serious Rejections 
-During First Year 
mg/d 1 
REJSER 
Creatinine at 3 Months CREAT3M0 
Creatinine at 6 Months mg/dl CREAT6M0 
*Other data collected albeit not analyzed include Patient 
Initials (PT) and Transplant Date (TXDATE). 
t-In tables and graphs prepared using the Statistical Analysis 
Systems software package, variables are referred to by these names. 

Table 2. Background Characteristics and Results 
Examined in Group F 
❖ 
Background Characteristics 
Variable Unit of Measure SAS Name 
Source of Kidney C=cadaveric SOURCE 
Age at Operation 
L=living related 
years AGE 




Peak Percent Antibodies percent ABPEAK 
Most Recent Percent Antibodies percent ABREC 
Results 
Mortality at 1 Year A=alive MORTAL 
Graft Loss at 6 Months 
D=dead 
Y=graft lost L0SS6M0 
Graft Loss at 1 Year 
N=graft functioning 
Y=graft lost LOSS 1YR 
Period Hospitalized 
-During First Six Months 
N=graft functioning 
days DAYS6M0 
-During First Year days DAYS1YR 
Rejection Episodes 
-During First Six Months REJ6M0 
-During First Year REJ1YR 
Serious Rejections 
-During First Year REJSER 
Creatinine at 3 Months rag /d 1 CREAT3M0 
Creatinine at 6 Months mg/dl CREAT6M0 
Interval Between Transplant 
and Cyclosporine Introduction days PRECYC 
*0ther data collected albeit not analyzed include Patient 
Initials (PT) and Transplant Date (TXDATE). 
t-In tables and graphs prepared using the Statistical Analysis 
Systems software package, variables are referred to by these names. 
' 
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Table 3. Additional Results Examined in Group C 
Variable 
Interval Between Transplant 
and Cyclosporine Introduction 




Interval Between Transplant 
and Switch from Cyclosporine 
to Azathioprine 
months SWITCH 
Number of Rejection Episodes 
within 3 Months of Switch 
POSTREJ 
Interval Between Cessation 
of Cyclosporine and 
Appearance of Rejection 
weeks TIMEREJ 
* I n tables and graphs prepared using the Statistical Analysis 
Systems software package, variables are referred to by these names 
« 
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Table 4. Comparison of 
for Group C 
Background Data 
Versus Group A 
Variable Group C Group A p value 
Number of Patients 26 49 
Percent Cadaveric 100% 57.1% .0001 
Age (years) 44.0+2.5 31.6+1.9 
t 
<.001 
Graft Number 1.4+.1 l.l+.l 
t 
NS 
Percent Peak Antibody 21.0+5.3 9.5+3.3 
t 
NS 
Percent Recent Antibody 9.2 +3.8 5.7 +2.4 
L 
NS 
Percent Diabetic 23.1% 8.1% NS 
Note: Standard Error of the Mean is given where appropriate. 
* by Chi-Squared 
t by Student's T-Test 
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Table 5. Summary of Background Data for Group F 
Variable Group F 
Number of Patients 9 
Percent Cadaveric 67% 
Age (years) 32.6+5.5 
Graft Number 1.0+0 
Percent Peak Antibody 26.1+10.4 
Percent Recent Antibody 18.7+11.4 
Percent Diabetic 0% 
Note: Standard Error of the Mean is given where appropriate. 
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Table 6. Comparison of Morbidity, Mortality, and Graft Loss 
Results for Group C Versus Group A 
Variable Group C Group A p value 
* 
1 Year Patient Survival 80.8% 91.8% NS 
& 
Graft Loss at 6 Months 19.2% 24.5 % NS 
Graft Loss at 1 Year 26.9% 26.5% NS 
Hospital Days - 6 Months 49.0+6.9 39.2+3.8 
t 
NS 
Hospital Days - 1 Year 64.0+13.0 44.0+4.7 
L 
NS 
Note: Standard Error of the Mean is given where appropriate. 
* by Chi-Squared 
t by Student's T-Test 
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Table 7. Summary of Morbidity, Mortality, and Graft Loss 
Results for Group F 
Variable Group F 
1 Year Patient Survival 100% 
Graft Loss at 6 Months 11.1% 
Graft Loss at 1 Year 11.1% 
Hospital Days - 6 Months 65.7+4.7 
Hospital Days - 1 Year 75.3+5.7 
Note: Standard Error of the Mean is given where appropriate. 

49 
Table 8. Comparison of Rejection Episodes and Graft Function 
Results for Group C Versus Group A 
Variable Group C Group A p value 
f- 
Rejections - 6 Months 0.9+.1 1.0+.1 NS 
4- 




Serious Rejections-1 Year 0.4+.1 0.8+.1 <.05 
Creatinine 
(mg/dl) 
- 3 Months 2.12+.15 1.50+.10 <.001 
Creatinine 
(mg/dl) 
- 6 Months 2.16+.20 1.67+.18 NS 
Note: Standard Error of the Mean is given where appropriate. 
* by Chi-Squared 
t by Student’s T-Test 
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Table 9. Summary of Rejection Episodes and Graft Function 
Results for Group F 
Variable Group F 
Rejections - 6 Months 1.4+.2 
Rejections - 1 Year 1.6+.2 
Serious Rejections-1 Year 1.3+.2 
Creatinine - 3 Months 
(mg/dl) 
1.66+.21 
Creatinine - 6 Months 
(mg/dl) 
1.67+.25 
Note: Standard Error of the Mean is given where appropriate. 
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Table 10. Frequency Distribution of Rejections in First Six Months 
Number of Rejections 
I 0 | 1 | 2 | 3| 4| 
----- +-+-+-+-+-+ 
Group A | | | | | | 
| 20.41 | 63.27 | 12.24 | 2.04 | 2.04 | 
I I I I I I 
-+ -+-+-+-+-+ 
Group C | | | | | | 
| 26.92 | 53.85 | 19.23 | 0.00 | 0.00 | 
I I I I I I 
-+- + ---+-■- +-+ 
The value in each cell is the percentage of patients in 
each group who had a given number of rejection episodes 
(ranging from 0 to 4) during the first six months. 
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Table 11. Frequency Distribution of Rejections in First Year 
Number of Rejections 
I 0| 1| 2| 3| 4 | 
-+-+--+-+-+-+ 
Group A | | | | | | 
| 20.41 | 53.06 | 22.45 | 2.04 | 2.04 | 
I I I I I I 
-,+-- + --• + .-+-+-+ 
Group C | | | | | | 
| 23.08 | 50.00 | 23.08 | 3.85 | 0.00 | 
I I I I I I 
--+-+-+-+---+-+ 
The value in each cell is the percentage of patients in 
each group who had a given number of rejection episodes 
(ranging from 0 to 4) during the first year. 
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Table 12. Frequency Distribution of Serious Rejections in First Year 
Number of Serious Rejections 
I 0 | 1 | 2 | 3 | 
-■ ---+-+-+-+ 
Group A | | | | | 
I 36.73 | 53.06 | 8.16 | 2.04 | 
I I I I I 
_____-- +-- +-___ +-+-+ 
Group C | | | | | 
| 57.69 | 42.31 | 0.00 | 0.00 | 
I I I I I 
■----..-+-+---+ 
The value in each cell is the percentage of patients in 
each group who had a given number of serious rejection 
episodes (ranging from 0 to 3) during the first year. 
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Table 13. Comparison of Background Data for 
Cadaveric Graft Recipients Only 
for Group C Versus Group A 
Variable Group C Group A p value 
Age (years) 44.0+2.5 34.1+2.2 <.01 
4-■ 
Graft Number 1.4+.1 1.2+.1 NS 
4- 




Percent Recent Antibody 9.2 +3.8 7.7 + 3.2 
L 
NS 
Percent Diabetic 23.1% 3.6% <.05 
Note: Standard Error of the Mean is given where appropriate. 
* by Chi-Squared 
t by Student's T-Test 
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Table 14. Comparison of Morbidity, Mortality, and Graft Loss 
Results for Cadaveric Graft Recipients Only 
for Group C Versus Group A 
Variable Group C Group A p value 
a! 
1 Year Patient Survival 80.8% 92.9% NS 
Graft Loss at 6 Months 19.2% 39.3% NS 
Graft Loss at 1 Year 26.9% 39.3% NS 
+- 




Hospital Days - 1 Year 64.0+13.0 49.6+_6.0 NS 
Note: Standard Error of the Mean is given where appropriate. 
* by Chi-Squared 
t by Student’s T-Test 
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Table 15. Comparison ■ 
Results 
of Rejection Episodes and Graft 
for Cadaveric Graft Recipients 
Function 
Only 
for Group C Versus Group A 
Variable Group C Group A p value 
f 
Rejections - 6 Months 0.9+.1 l.l+.l NS 
t 
Rejections - 1 Year 1.1+.2 1.3+. 1 NS 
t 
Serious Rejections-1 Year 0.4+.1 1.0+.1 .0001 
t 
Creatinine - 3 Months 
(mg/dl) 
2.12+.15 1.71+.19 NS 
t 
Creatinine - 6 Months 
(mg/dl) 
2.16+.20 1.73+.19 NS 
Note: Standard Error of the Mean is given where appropriate. 
* by Chi-Squared 
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Figure 1. Comparison of Mean Ages of Study Groups 
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Figure 4. Histogram of Three Month Creatinine Values 
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Figure 5. Histogram of Six Month Creatinine Values 
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Figure 6. Histogram of Three Month Creatinine Values 
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Figure 7. Histogram of Six Month Creatinine Values 
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Figure 8. Histogram of Three Month Creatinine Values 

























Figure 9. Histogram of Six Month Creatinine Values 
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TABLE Al. SUMMARY OF DATA COLLECTED ON RENAL TRANSPLANT RECIPIENTS 
D C C 
I L L D D R R P T 
T S A A M 0 0 A A R R R E E P S 0 I 
X G 0 B G B A 0 S S Y Y E E E A A R w s M 
D R U E R P B R S s S S J J J T T E I T E 
0 A 0 R A T A E R T 6 1 6 1 6 1 S 3 6 C T R R 
B T U P C G I F A E A M Y M Y M Y E M M Y C E E 
S E P T E E C T K C L 0 R 0 R 0 R R 0 0 C H J J 
1 021983 A M.K. C 38 N 1 0 0 A N N 35 50 1 2 2 2.4 2.3 
2 040183 A S.G. C 27 N 2 95 60 A N N 61 88 1 2 2 2.1 1.8 
3 040883 A D.S. c 48 N 1 3 0 A Y Y 152 163 2 2 2 , 
4 040983 A T.M c 35 N 1 3 0 A Y Y 27 27 1 1 1 . 
5 041483 A T.G. c 34 N 1 48 33 D Y Y 45 45 1 1 1 . 
6 042883 A K.G. L 32 N 1 • . A N N 14 14 0 0 0 1.2 1.2 
7 052283 A K.W. C 32 N 1 0 0 A Y Y 55 55 1 1 1 . . 
8 053183 A B.C. L 27 N 1 0 0 A N N 39 39 1 1 0 2.4 2.3 
9 060783 A H.B. C 23 N 1 5 0 A N N 18 18 0 0 0 1.7 1.4 
10 061783 A S.S. C 22 N 1 0 0 A N N 29 29 1 1 1 2.1 1.7 
11 062583 A A. L. c 26 Y 1 3 0 A N N 20 20 0 0 0 1.0 1.0 
12 070683 A R.T. c 22 N 2 50 30 A N N 55 55 3 3 1 3.4 4.2 
13 070783 A G.R. L 20 N 1 0 0 A N N 19 19 1 1 0 1.2 1.0 
14 071283 A N.B. L 37 N 1 . . A N N 17 17 1 1 0 1.0 1.0 
15 071483 A S.F. L 19 N 1 0 0 A N N 48 48 2 2 1 1.5 1.6 
16 072683 A C.B. L 16 N 1 , A N M 21 21 1 1 0 1.6 1.5 
17 072883 A J.M. C 41 N 1 3 3 A Y Y 20 20 1 1 1 • . 
18 080483 A J.V. L 57 N 1 0 0 A N N 14 30 0 0 0 2.0 2.1 
19 080483 A R.B. L 15 N 1 . A N N 59 59 0 0 0 1.1 1.0 
20 081383 A W.K. C 11 N 1 30 10 A Y Y 8 8 1 1 1 . . 
21 081783 A F.S. C 45 N 1 20 0 A N N 40 40 1 1 1 1.5 1.3 
22 082083 A J.B. C 18 N 2 5 3 A N N 47 47 1 1 1 1.1 0.9 
23 090283 A R.M. C 41 N 3 10 10 A N N 61 71 1 1 1 2.0 2.0 
24 091083 A A. J. C 42 N 1 3 0 A N N 38 38 1 1 1 . 1.6 
25 091483 A D. A . C 40 N 1 0 0 A N N 61 61 2 2 1 . 1.9 
26 091883 A D.L. C 40 N 1 0 0 A Y Y 51 51 1 1 1 . . 
27 092283 A D.M. L 40 N 1 • . A N N 17 53 1 2 1 1.1 1.2 
28 092883 A W.K. C 11 N 2 58 58 A N N 35 35 1 1 1 0.6 2.0 
29 110683 A A. S . C 50 N 1 0 0 A Y Y 61 61 1 1 1 . . 
30 111083 A M.H. L 6 N 1 . . A N N 12 12 0 0 0 0.4 0.5 
31 112983 A G.L. C 54 N 1 0 0 A Y Y 53 53 1 1 1 . . 
32 121383 A J.M. L 47 N 1 . . A N N 28 28 1 1 0 1.2 1.1 
33 012684 A W.G. L 29 N 1 . . A N N 40 40 1 1 1 1.3 . 
34 020984 A M. A. L 16 N 1 . . A N N 13 13 0 0 0 1.0 1.2 
35 032184 A D.O. C 44 N 1 5 0 D Y Y 60 60 1 1 1 . . 
36 032384 A M.L. L 50 Y 1 0 0 A N N 25 25 1 1 0 1.3 . 
37 032984 A R.B. L 48 Y 1 0 0 D N Y 95 165 4 4 3 2.1 6.3 
38 040984 A T.S. C 33 N 1 3 0 A N N 64 64 2 2 1 2.2 1.9 
39 041084 A Y.S . L 33 Y 1 3 0 D Y Y 1 1 0 0 0 . . 
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TABLE Al. SUMMARY OF DATA COLLECTED ON RENAL TRANSPLANT RECIPIENTS 
(continued) 
D C C 
I L L D D R R P T 
T S A A M 0 0 A A R R R E E P S 0 I 
X G 0 B G B A 0 S S Y Y E E E A A R W S M 
D R u E R P B R s S S S J J J T T E I T E 
0 A 0 R A T A E R T 6 1 6 1 6 1 S 3 6 C T R R 
B T U P C G I F A E A M Y M Y M Y E M M Y C E E 
S E P T E E C T K C L 0 R 0 R 0 R R 0 0 C H J J 
40 051784 A D.B. L 38 N 1 3 3 A N N 20 41 1 2 0 1.7 1.9 
41 052284 A W.B. C 42 N 1 5 5 A N N 35 35 1 1 1 1.0 1.0 
42 053084 A A. T. C 15 N 1 3 0 A N N 37 37 2 2 0 1.2 1.2 
43 062184 A L.R. L 11 N 1 . • A N N 23 23 0 0 0 0.9 0.8 
44 073184 A J.L. L 17 N 1 . . A N N 64 64 1 1 1 1.6 1.9 
45 081184 A J. A. C 41 N 1 3 3 A N N 83 114 1 2 2 1.7 1.4 
46 091184 A L.L. C 38 N 1 0 0 A N N 32 32 1 1 1 . . 
47 100984 A A. B. C 43 N 1 0 0 A Y Y 11 11 1 1 1 . # 
48 103084 A D.O. L 22 N 1 0 0 A N M 18 18 0 0 0 1.1 1.2 
49 112784 A K.P. L 13 N 1 0 0 A N N 39 39 2 2 1 1.3 1.3 
50 120383 C M.W. C 54 N 1 13 5 D N Y 101 116 1 1 0 3.9 2.1 1 
51 120483 C B.G. C 50 N 1 0 0 A N Y 53 57 1 1 0 2.1 3.2 0 
52 121383 c L.I . C 62 N 1 33 8 A N N 101 148 1 1 0 1.6 2.2 0 7 0 
53 122483 c C.H. C 52 N 3 3 3 A N N 23 23 0 0 0 2.8 2.7 0 6 0 
54 122483 c H. V. C 28 N 3 60 33 A Y Y 18 18 1 1 1 . . 0 . 
55 012984 c K. J. C 34 Y 1 13 0 D Y Y 72 72 1 1 0 2.4 . 1 . . 
56 021184 c M.B. C 23 N 3 95 93 D Y Y 167 351 2 2 1 . . 0 . . 
57 021684 c W.R. C 49 Y 1 3 3 A N N 45 45 1 1 0 1.8 2.2 0 9 0 
58 022284 c R.B. C 51 Y 1 30 30 A N N 19 45 0 1 0 1.6 1.5 0 7 1 8 
59 030784 c D.P. C 35 Y 1 10 10 A N N 16 32 0 0 0 1.5 1.3 0 7 0 
60 031384 c E.P. c 49 N 1 18 5 A N N 36 36 1 1 0 1.7 1.5 0 6 0 
61 031584 c S.H. c 55 N 1 0 0 A N N 65 65 2 2 1 2.3 3.5 0 10 0 
62 032884 c R.V. c 51 Y 1 0 0 D Y Y 3 3 0 0 0 . • 1 • • 
63 033084 c D.B. c 24 N 2 23 23 A N N 38 38 1 1 0 2.5 . 0 3 0 
64 042684 c C.M. c 45 N 2 0 0 A N N 38 38 1 1 1 2.1 2.9 0 7 0 
65 062084 c J.D. c 39 N 1 3 0 A N N 72 72 2 2 1 2.0 1.6 27 . . 
66 072484 c M.M. c 50 N 1 33 3 D Y Y 57 57 1 1 1 . . 1 . . 
67 072984 c I .P. c 51 N 1 3 0 A N N 45 54 1 1 1 3.9 4.5 0 6 1 2 
68 091284 c F.S . c 56 N 1 15 5 A M N 28 52 1 3 1 2.4 2.5 19 7 1 4 
69 110484 c J. A. c 32 N 1 95 3 A N N 64 105 1 2 1 1.8 1.7 3 4 0 
70 121484 c L.M. c 31 Y 1 60 0 A N N 72 72 2 2 1 2.3 0 . 
71 122884 c L. A. c 12 N 2 5 0 A N N 26 26 0 0 0 1.2 1.2 7 . . 
72 013085 c F.M. c 60 N 1 5 0 A N N 17 29 0 0 0 1.2 1.2 0 4 0 
73 020185 c R.K. c 51 N 2 5 3 A N N 25 37 0 1 0 1.6 1.6 4 6 1 1 
74 020885 c H.M. c 57 N 1 8 0 A N N 36 36 1 0 0 2.1 1.8 17 4 0 
75 021785 c P.T. c 42 N 2 13 13 A N M 38 38 2 2 1 1.8 1.8 19 6 0 
76 081883 F L.D. c 40 N 1 77 77 A N N 47 93 1 2 2 1.7 1.5 197 . . 
77 112383 F A. W. c 56 N 1 8 0 A N N 79 79 2 2 2 1.7 1.7 30 . . 
78 012084 F M.M. c 8 N 1 0 0 A N N 44 44 1 1 1 0.6 0.7 27 . . 

75 
TABLE Al. SUMMARY OF DATA COLLECTED ON RENAL TRANSPLANT RECIPIENTS 
(continued) 
D C C 
I L L D D R R P T 
T S A A M 0 0 A A R R R E E P S 0 I 
X G 0 B G B A 0 S S Y Y E E E A A R W S M 
D R u E R P B R S s S S J J J T T E I T E 
0 A 0 R A T A E R T 6 1 6 1 6 1 S 3 6 C T R R 
B T U P C G I F A E A M Y M Y M Y E M M Y C E E 
S E P T E E C T K C L 0 R 0 R 0 R R 0 0 C H J J 
79 032284 F I .M. C 26 N 1 45 45 A Y Y 73 73 1 1 1 53 
80 032784 F S.P. L 12 N 1 3 3 A N N 53 53 1 1 1 1.0 1.7 97 
81 051784 F T.B. C 25 N 1 20 3 A N N 75 86 2 2 2 2.1 1.2 45 
82 052484 F J.B. L 38 N 1 . . A N N 70 79 2 2 1 2.2 2.8 112 
83 080284 F A. S. L 52 N 1 . . A N N 81 96 2 2 1 2.2 . 98 
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